Abiopharma

News list

(75% Positive) Bicycle Therapeutics plc (BCYC) Provides Update on included for Bicycle’s wholly owned oncology pipeline

Full text

News bot Oct. 2, 2025, 12:58 p.m.
📋 Bicycle Therapeutics plc (BCYC) - Clinical Trial Update

Filing Date: 2022-07-12

Accepted: 2022-07-12 16:00:36

Event Type: Clinical Trial Update
Event Details:
Bicycle Therapeutics (BCYC) Announces Clinical Trial Update Bicycle Therapeutics (BCYC) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: included, collaboration
Diseases/Conditions: Bicycle’s wholly owned oncology pipeline
Collaboration: Bicycle
targeting Nectin-4, a well-validated tumor antigen; and BT7480
targeting EphA2; BT8009
targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval: Not available
- Executive Changes: Not available
Structured Data:
- Company Name: Bicycle Therapeutics
- CIK: 0001761612
- Ticker Symbol: BCYC
- Period End Date: 2022-07-12
- Document Type: 8-K